Differential effects of heat shock protein 90 and serine 1179 phosphorylation on endothelial nitric oxide synthase activity and on its cofactors

14Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Endothelial nitric oxide synthase (eNOS) is responsible for maintaining systemic blood pressure, vascular remodeling and angiogenesis. Previous studies showed that bovine eNOS serine 1179 (Serine 1177 for human eNOS) phosphorylation enhanced NO synthesis. Meanwhile, heat shock protein 90 (Hsp90) plays a critical role in maintenance of eNOS structure and function. However, the regulatory difference and importance between Serine 1179 phosphorylation and Hsp90 on eNOS activity have not been evaluated. In current studies, S1179D eNOS was employed to mimic phospho-eNOS and exhibited markedly increased enzyme activity than wild type eNOS (WT eNOS). Hsp90 showed a dose-dependent increase for both WT eNOS and S1179D eNOS activity at the presence of all eNOS cofactors, such as Calcium/Calmodulin (Ca2+/CaM), BH4, and NADPH etc. The enhancement effects were abolished by dominant-negative mutant Hsp 90 protein. ENOS-cofactors dynamic assay showed that Hsp90 enhanced WT eNOS affinity to NADPH, L-arginine, and CaM but not to Ca2+ and BH4. The impact of eNOS Serine 1179 phosphorylation and Hsp90 on eNOS affinity to cofactors has also been compared. Different from the effect of Hsp90 on eNOS affinity to specific cofactors, Serine 1179 phosphorylation significantly increased eNOS affinity to all cofactors. Moreover, VEGF-induced eNOS phosphorylation in bovine aortic endothelial cells (BAECs) and more NO generation from eNOS compared to control. Inhibition of Hsp90 by geldanamycin decreased eNOS activity and decreased endothelial viability. In conclusion, by changing eNOS structure, Hsp90 profoundly affected eNOS functions, including change of affinity of eNOS to cofactors like Ca2+, L-arginine, BH4 and further affecting NO generation capability. These specific cofactors regulated by Hsp 90 could become potential therapeutic targets of the eNOS-related diseases in future.

Figures

  • Fig 1. Hsp90 enhances both WT eNOS and S1179D eNOS activity. Purified WT eNOS and S1179D eNOS activities were assayed by monitoring the conversion of L-14C-arginine to L-14C-citrulline in the presence of different concentration of Hsp90. (A) Hsp90 enhanced WT eNOS as a dose-dependently and these enhancements were inhibited by dominant mutant Hsp90 (DNHsp90) (n = 5, *P<0.05, Hsp90 treatment groups compared to control). (B) Moreover, Hsp90 had higher enhancement effect on S1179D eNOS than it had on WT eNOS (n = 5, *, P<0.05 Hsp90 treatment groups compared to control).
  • Fig 2. Hsp90 enhanced WT eNOS but not S1179D eNOS affinity to NADPH. (A) Hsp90 augmented both WT eNOS and S1179D eNOS activity in the presence of NADPH. The effect of Hsp 90 on enzymatic activity of WT eNOS and S1179D eNOS was assayed by monitoring the conversion of L14C-arginine to L-14C-citrulline in the presence of indicated concentration of NADPH (n = 5). (B) NADPH-eNOS activity dynamic assay showed that Hsp90 enhanced eNOS affinity to NADPH in WTeNOS. In contrast, mutation of S1179D significantly enhanced eNOS affinity to NADPH in the absence and presence of Hsp90 compared to their control (EC50, P<0.05; n = 5).
  • Fig 3. Hsp90 enhanced WT eNOS but not S1179D eNOS affinity to L-arginine. (A) Hsp90 augmented both WT eNOS and S1179D eNOS activity capacity in the presence of L-arginine (n = 5). (B) L-arginine -eNOS activity dynamic assay showed that Hsp90 enhanced WTeNOS (EC50, P<0.05; n = 5) but not mutant S1179D sensitivity to L-arginine (EC50, P>0.05; n = 5). However, mutation of S1179D significantly enhanced eNOS affinity to Larginine compared to their WT eNOS control in the absence and presence of Hsp90 (EC50, P<0.05; n = 5).
  • Fig 4. Hsp90 enhanced WT eNOS but not S1179D eNOS affinity to Calmodulin. (A) Hsp90 augmented both WT eNOS and S1179D eNOS activity capacity in the presence of calmodulin (n = 5). (B) Calmodulin -eNOS activity dynamic assay showed that Hsp90 enhanced WTeNOS (EC50, P<0.05; n = 5) but not mutant S1179D sensitivity to calmodulin (EC50, P>0.05; n = 5). However, mutation of S1179D significantly enhanced eNOS affinity to calmodulin compared to their WT eNOS control in the absence or presence of Hsp90 (EC50, P<0.05;n = 5).
  • Fig 5. Hsp90 did not enhance either WT eNOS or S1179D eNOS affinity to calcium. (A) Hsp90 augmented both WT eNOS and S1179D eNOS activity capacity in the presence of calcium. The effect of Hsp 90 on enzymatic activity of WT eNOS and S1179D eNOS was assayed by monitoring the conversion rate of L-14C-arginine to L-14C-citrulline in the presence of indicated concentration of calcium chloride (n = 5). (B) Calcium chloride -eNOS activity dynamic assay showed that Hsp90 did not change either WTeNOS or mutant S1179D sensitivity to calcium ((EC50, P>0.05; n = 5). On the other hand, mutation S1179D significantly enhanced eNOS affinity to calcium comparing to their WT eNOS control in the absence or presence of Hsp90 (EC50, P<0.05; n = 5).
  • Fig 6. Hsp90 did not enhance either WT eNOS or S1179D eNOS affinity to BH4. (A) Hsp90 augmented both WT eNOS and S1179D eNOS activity capacity in the presence of BH4. The effect of Hsp 90 on enzymatic activity of WT eNOS and S1179D eNOS was assayed by monitoring the conversion rate of L-14C-arginine to L-14C-citrulline in the presence of indicated concentration of BH4 (n = 5). (B) BH4-eNOS activity dynamic assay showed that Hsp90 did not change either WTeNOS or mutant S1179D sensitivity to BH4 (EC50, P>0.05; n = 5). In contrast, mutation of S1179D significantly enhanced eNOS affinity to BH4 compared to their WT eNOS control in the absence or presence of Hsp90 (EC50, P<0.05;n = 5).
  • Fig 7. Inhibition of Hsp90 abolished VEGF-mediated eNOS phosphorylation and decreased NO production and cell viability in BAECs. (A and B) BAECs were treated 50ng/mL VEGF indicated time. The cell lysates were harvested for western blot using indicated antibodies (*, P>0.05, compared to control; n = 3). (C and D) In different experiments, BAECs were treated with 50ng/mL VEGF in the
  • Fig 8. Dominant negative Hsp90 inhibited VEGF-mediated eNOS phosphorylation and NO generation from BAECs. (A and B) Overexpression of DNHsp90 in BAECs increased Hsp90β expression and significantly inhibited VEGF-mediated eNOS phosphorylation (P<0.05 compared to control; n = 4); (C) Fe2+-MGD-NO adduct signal density assay showed that DNHsp90 also significantly inhibited VEGF-mediated NO generation from BAECs (P<0.05 compared to control; n = 6).

References Powered by Scopus

5939Citations
732Readers
Get full text
3255Citations
3415Readers

This article is free to access.

Get full text

Cited by Powered by Scopus

23Citations
32Readers

This article is free to access.

This article is free to access.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Chen, Y., Jiang, B., Zhuang, Y., Peng, H., & Chen, W. (2017). Differential effects of heat shock protein 90 and serine 1179 phosphorylation on endothelial nitric oxide synthase activity and on its cofactors. PLoS ONE, 12(6). https://doi.org/10.1371/journal.pone.0179978

Readers over time

‘17‘18‘19‘20‘21‘23‘2401234

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 7

64%

Professor / Associate Prof. 2

18%

Researcher 2

18%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 7

64%

Medicine and Dentistry 2

18%

Agricultural and Biological Sciences 1

9%

Chemistry 1

9%

Save time finding and organizing research with Mendeley

Sign up for free
0